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1 INTRODUCTION 
1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most frequent malignancy worldwide [1]. 
Moreover, its incidence increases due to hepatitis B and C viral infections, especially 
in countries where those viral infections are endemic such as China [2]. In countries 
with a high immunization rate against hepatitis B, cirrhosis is the main risk factor of 
hepatocellular carcinoma, mostly induced by alcohol abuse. Further risk factors are 
hemochromatosis, diabetis mellitus type II, and environmental toxins like Aflatoxin. 
The various factors and the often poor prognosis of HCC bring this disease into the 
focus of several treatment studies. Compared to other solid tumors, HCC is 
characterized by high levels of vascularization. The status of angiogenesis correlates 
with cancer progression and prognosis. Therefore, antiangiogenic strategies are 
suggested for treatment of HCC [3] due to survival advantages, as revealed in recent 
studies[4, 5]. 
 
1.2 Angiogenesis as a key player in tumor development 
As angiogenesis performs a crucial and critical role in the development of many solid 
cancers [6-10], it’s worthwhile to take a look at this phenomenon and its mechanism. 
Solid tumors are not vascularized as long as they are smaller then 2-
3 cubic millimeters [11], because cells get oxygen and nutrients by diffusion 
comparable with small organisms like Drosophila melanogaster [12]. The angiogenic 
switch is a prerequisite for further tumor development and growth. The mechanism 
taking place between angiogenic switch and sprouting of new vessels into the 
hypoxic tumor tissue have been extensively reviewed in recent publications [12, 13]. 
The process of angiogenesis starts with the insufficient supply with oxygen in the 
cells, which are located around the core area of the solid tumor. Hypoxia inducible 
factor 1α (HIF-1α) switches on a complex signalling cascade [12]. The proangiogenic 
vascular endothelial growth factor (VEGF) family [14, 15] triggers the sprouting of an 
endothelial cell, the so called tip cell [16]. In the following sprouting process further 
signalling molecules, like neuropilins, Notch, phosphatidylinositol-
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glycan biosynthesis class F protein (PIGF), and fibroblast growth factor (FGF), play 
an important role: they ensure the leading position of the tip cell and assure the 
directed growth of so called stalk cells [16]. Finally, VE-cadherin (vascular 
endothelial), CD34, VEGF, and hedgehog establish the lumen of the new vessel.  
Functional blood vessels provide the basis of tissue homeostasis and growth with the 
supply of oxygen and nutrients and the elimination of metabolic degradation products 
[12]. Furthermore, the neovascularization improves the state of uncontrolled 
proliferation characteristic of tumor cells and is also thought to be an excellent 
indicator of its metastatic potential [17, 18]. Based on this knowledge, antiangiogenic 
therapies were introduced into clinic. The idea that blockage of angiogenesis could 
be a target in cancer therapy was postulated by Judah Folkman in 1971 [19]. Since 
then, many antiangiogenic drugs like antibodies against VEGF or its receptors and 
tyrosin kinase inhibitors were successfully used in cancer treatment against various 
solid tumors. For example: The monoclonal antibody against VEGF Bevacizumab 
was approved in combination with other chemotherapy for the treatment of metastatic 
colorectal cancer [20], non-small-cell lung cancer [21], metastatic renal cell 
carcinoma [22, 23], and metastatic breast cancer [24]. In addition, well-known 
cytotoxic drugs like cyclophosphamide (CPA) showed antiangiogenic capacities and 
were examined in different studies on their impact on angiogenesis [25, 26]. 
 
1.3 Cyclophosphamide – Pharmacology and medical 
uses 
Cyclophosphamide is a well known cytostatic drug which is used in many therapeutic 
regimes against a bright range of tumors. As the oral application leads to 
bioavailability of more than 75% and also an intravenous (i.v.) application is possible, 
cyclophosphamide captured the market since its launch 1958. It is now state of the 
art in combination therapies against breast cancer, non Hodgkin lymphoma, acute 
lymphatic leukemia, and other sarcomas and blastomas. As a maximum tolerated 
dose (MTD) chemotherapy cyclophosphamide is used with 600 - 1000 mg/m² body 
surface area for intravenous application and depends on the kind of diagnosed tumor 
[27]. Uneffected by the way of application cyclophosphamide as a prodrug needs to 
be activated by the cytochrome P450 enzymes in the liver.  
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A member of the cytochrome P450, family 2, subfamily B (CYP2B) enzymes 
hydroxylates cyclophosphamide to 4-hydroxyphosphamide. This and its tautomer 
aldophosphamide are the transport-form and they diffuse into the tumor-cells. There, 
the last activation step takes place and aldophosphamide is decomposed into two 
compounds, acrolein and the cytotoxic phosphoramide mustard [28]. This active 
phosphoramide mustard alkylates irreversibly DNA and leads thereby to apoptosis 
[29]. 
 
1.4 Metronomic schedule of cyclophosphamide  
The use of CPA in a preclinical antiangiogenic, metronomic regimen revealed 
encouraging results in terms of tumor growth suppression and survival in an in vivo 
rat model of hepatocellular carcinoma [30]. The metronomic treatment regimen is 
characterized by significantly reduced side effects, compared to conventional MTD 
chemotherapy administration and by anti-tumor activity in respect to its 
antiangiogenic properties. Preferentially, the metronomic treatment regimens target 
genetic stable tumor vessel endothelial cells and thus, the development of resistance 
against the therapy should be avoided [31, 32]. However, several studies point 
towards the induction of in vivo chemoresistance mechanisms that let tumors escape 
from metronomic CPA therapy [33-35]. 
 
1.5 Resistance during chemotherapeutic treatments 
Many different mechanisms against chemotherapeutic agents are well known 
because of their efficiency in overcoming cancer therapies. The focus is on possible 
escape tools of cancer cell during CPA treatment (Figure 1), as CPA was used for 
several experiments in this thesis. In case of CPA, a diminished uptake of the 
metabolites 4-hydroxycyclophosphamide and aldophosphamide is one of the 
mechanisms. Additionally, a higher efflux of these two intermediates by unspecific 
pumps makes the therapy inefficiently. Often detoxicating enzymes are upregulated 
and metabolize the drug or his intermediates to inefficient, non-toxic agents. In all 
three cases a lower intracellular dose leads to a lower efficiency against the mutated 
cell. Further escape mechanisms are modifications at the effector points. As CPA is 
Introduction 6 
an alkylating agent, faster repairing of DNA damages saves the cell survival. 
Moreover, arresting of important transmitters or mutations of these transmitters helps 
cancer cells to overcome chemotherapy, because thereby apoptosis is avoided [36]. 
 
 
 
Figure 1 Possible escape mechanisms with its tools during CPA therapy. Diminished 
uptake (1), a higher number of efflux pumps on the cell surface (2), an upregulated 
detoxification by enzymes (3+4), and more DNA repairing enzymes (5) lead to a diminished 
effectiveness of CPA. Interruption of the apoptosis pathway is (6) 
 
1.6 An in vivo chemoresistance HCC xenograft model 
A novel in vivo chemoresistance HCC xenograft model was developed by Dr. Michael 
Günther in his PhD thesis (LMU Munich, 2007). Subcutaneous human hepatocellular 
carcinoma HUH-7 tumors were established in severe combined 
immunodeficiency (SCID) mice by injection of 5x106 HUH-7 cells into the loin area of 
the animals. The untreated control group showed the aggressive manner of these 
tumors with a tumor volume doubling time of 2.5 days. With the metronomic 
scheduled CPA treatment of 75 mg/kg body weight every six days, Dr. Günther could 
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reach a growth delay and the tumor size of treated mice was constant up to day 75 
after implantation. Afterwards, HUH-7-tumors in treated animals showed a volume 
doubling time of 3.5 days despite ongoing treatment and therefore, a resistance 
against therapy [37]. 
 
HUH-wt
HUH-REISO
no treatment CPA treatment
75mg/kg 
CPA every 
six day 
i.p. 
reisolation
untreated 
control 
HUH-PAS
 
 
Figure 2: The human hepatocellular xenograft mouse model. Subcutaneous human 
HUH-7 tumours were established in SCID mice by injection of 5×106 HUH-7 cells into the 
flanks of animals (n=6). CPA treatment was started on day 12 after tumour implantation with 
75 mg/kg CPA every six days. Metronomic scheduled CPA treatment resulted in significant 
tumour growth delay [37]. 
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1.7 Aims of the thesis 
In the current thesis, changes in transcription factors, controlling plasticity and 
stemness of tumor cells in an in vivo chemoresistance HCC xenograft mouse model 
should be investigated. The main objective was to discover targets for the therapeutic 
and also the diagnostic medicine in this chemoresistance model. On the one side, 
those should offer the correct diagnosis at an earlier time-point and on the other side, 
new options in therapy to overcome or even prevent resistance. Of course, many 
steps lie between the first identification and the successful therapy, but the origin of 
the problem has to be known for being able to solve the problem.  
Resistant HCC xenografts were generated by metronomically scheduled CPA 
treatment in SCID mice, resulting in resistant tumor outgrowth after an initial 
chemoresponsive phase of 10 weeks. The histological analysis of the in vivo 
generated tumor tissue revealed significant changes in tissue organization and blood 
flow. In cell culture, cultivated cells of those in vivo generated cell lines lacked 
chemoresistance. But re-xenografted tumors from HUH-REISO cell culture 
manifested immediate chemoresistance, lacking an initial response phase.  
Therefore, a more detailed view on the intracellular fingerprint of these cells should 
be generated: In order to detect gene expression associated with the 
chemoresistance and its development, expression levels of different markers had to 
be determined. Notch homolog 1, translocation-associated (Drosophila) (Notch-1), 
downstream hairy and enhancer of split-1 (HES-1), and neurogenic locus notch 
homolog protein 3 (Notch-3) are often described to have an important part in 
angiogenesis and were therefore part of the planned investigations. Moreover, the 
thesis should focus on the popular markers of stemness thymocyte antigen 1 (Thy-1), 
octamer binding transcription factor 4 (Oct-4), sex determining region Y box 2 (Sox-2) 
and Nanog.  In in vivo passaged control tumor xenografts and in their resistant tumor 
counterparts with and without therapeutic pressure they should be investigated. 
Furthermore, several aspects of cell differentiation should be tracked in specialized 
in vitro models, mimicking features of environmental properties of solid tumors. 
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2 MATERIALS AND METHODS 
2.1 Cell culture  
Cell culture media, antibiotics, fetal bovine serum (FBS) and trypsin/EDTA solution 
were purchased from Invitrogen GmbH (Karlsruhe, Germany). Human hepatoma 
cells (HUH-7) (JCRB0403) were cultured in a mixture of Ham’s-F12 and Dulbecco’s 
modified Eagle’s medium (DMEM) in a ratio of 1:1 supplemented with 10% FBS. 
Cells were grown at 37° C in 5% CO2 in a humidified atmosphere. HUH-7 cells were 
cultured without antibiotics for at least 3 – 4 passages before tumor cell implantation 
and were harvested just as reaching approx. 70% confluency. 
 
2.2 In vivo animal models 
Male SCID mice (CB17/lcr-PrkdcSCID/Crl) (8–10 weeks) were housed in individually 
vented cages under specific pathogen free conditions with a 12 hours day/night cycle 
and with food and water ad libitum. HUH-7 cells were cultured as described above. 
The number of 106 HUH-7 cells in 100 µl phosphate buffered saline (PBS) was 
injected subcutaneously with a 25 G needle (Braun, Melsungen, Germany) into the 
flank of SCID mice. The animals were checked regularly for tumor progression. The 
moment that tumor volume reached the size of at least 10 mm3, tumor progression 
was monitored using a digital measuring slide (Digi-Met, Preisser, Gammertingen). 
Each measurement consisted of three diameters, length (a), width (b), and height (c). 
Tumor volume was calculated by the formula a × b × c × π / 6 (with a, b and c 
indicating the three diameters and π / 6 as correction factor for tumor shape). Tumor 
volume doubling time (TVDT) was calculated with TVDT = ln2x (t2-t1) / ln[V(t2)/V(t1)]. 
All animal experiments were performed with 6 animals per group. All animal 
procedures were approved and controlled by animal experiments ethical committee 
of Regierung von Oberbayern, District Government of Upper Bavaria, Germany and 
carried out according to the guidelines of the German law of protection of animal life.  
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2.3 Isolation of tumor cells 
For isolation of tumor cells, mice were sacrificed at the first therapy endpoint (see 
Figure 3 and Table 1) with CO2. Skin was cleaned and sanitized with isopropanol 
(70% in water v/v), followed by drying under sterile conditions. Tumors were collected 
and immediately immerged in a 1:1 mixture of Ham’s-F12 and 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FBS and 
2% penicillin/streptomycin (Biochrom, Berlin, Germany). Tumor tissue was reduced 
to small sections under sterile conditions. Pieces were chosen randomly from all 
areas of the tumor. This procedure was repeated until the tumor tissue was 
homogenized. The obtained homogenized cell suspension was diluted with fresh 
penicillin/streptomycin containing Ham’s-F12 and DMEM 1:1. The tumor cell 
containing suspension was transferred to tissue 6-well-plates (TPP, Trasadingen, 
Switzerland) and incubated under standard conditions (37 °C, 5% CO2) in a 
humidified atmosphere for 2 - 3 days. Just as cells attached to the bottom of the 
plate, medium was replaced every second day, until cells reached a confluence of 
about 70%. Obtained cell lines (HUH-PAS, HUH-REISO) were defined in table 1. 
Reimplantation studies were performed by injection of 106 HUH-7 tumor cells at a 
passage number below 10.  
 
 
 
Table 1 Abbreviations of cell lines and their origin 
 
2.4 Transmitted light microscopy of cell culture 
Transmission light microscopy of living cells growing as a monolayer in a 75 cm3 cell 
culture flask (TPP, Switzerland) was performed using an Axiovert 200 microscope 
(Carl Zeiss, Jena, Germany) with an Infinity 2 camera and Infinity capture software 
(both: Lumenera corporation, Ottawa, Canada).  
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2.5 Chemotherapy 
Cyclophosphamide (CPA) (Sigma, Taufkirchen, Germany) was solved in PBS (10 
mg/ml) and applied intraperitoneally (i.p.). 75 mg/kg CPA solution was administered 
with a 25 G needle (Braun, Melsungen, Germany). The application of the CPA 
solution was carried out every 6 days. A single dose of each application was based 
on animal body weight. Toleration of CPA treatment was monitored by regular 
measurement of body weight. The vehicle group (PBS) and the drug treatment group 
(CPA dissolved in PBS) were housed separately. 
 
2.6 Hematoxylin and eosin stain (HE stain) of tumors 
Cryosections were fixed with 4% paraformaldehyde and stained with haematoxylin 
(Sigma, St. Louis, USA) for 30 minutes. After washing with PBS and distilled water 
(aqua dest.), sections were incubated with eosin (1:100 in aqua dest.) (Sigma, St. 
Louis, USA) for 4 minutes. Afterwards, sections were washed with aqua dest., 
embedded with PBS and analyzed by transmission light microscopy at the Axiovert 
200 microscope (Zeiss, Jena, Germany). 
 
2.7 Immunohistochemistry 
For immunohistochemistry, tumors were embedded in tissue freezing medium (Jung, 
Nussloch, Germany). They were cut into sections of 5 - 10 µm thickness with a 
cryomicrotome (Leica CM 3050s, Wetzlar, Germany) at − 20 °C. Sections were 
transferred to a microscope slide, tissue freezing medium was removed and tissue 
was fixed with 4% paraformaldehyde (in PBS). Afterwards, sections were rehydrated 
and washed with blocking solution (PBS containing 5% FBS) prior to antibody 
incubation. Antibodies, which were used for staining are listed in Table 2. All primary 
antibodies were diluted 1:200 in blocking solution. After incubation for 12 hours at 
4 °C in humidified atmosphere, sections were washed repeatedly with blocking 
solution followed by secondary antibody staining. Secondary antibodies were diluted 
1:400 in blocking solution and sections were incubated for 2 hours at room 
temperature in humidified atmosphere. Sections were washed with blocking solution 
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repeatedly, before fluorescence analysis at the Axiovert 200 microscope (Zeiss, 
Jena, Germany) using appropriate filter sets.  
 
 
 
 
Table 2 Antibodies used for immunohistochemistry. 
 
2.8 Flow cytometry 
2.8.1 Sample preparation in vitro 
Cells, grown at 37 °C in 5% CO2, were harvested, just as reaching approximately 
70% confluency. After counting, 300,000 cells were subjected to each antibody 
staining. 
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2.8.2 Immunostaining for FACS analysis 
Cells were washed twice with 5% fetal bovine serum FBS in PBS (FACS-buffer) prior 
to imunnostaining. Primary antibodies were dissolved 1:200 in FACS-buffer and cells 
were incubated with 200 µl of this dilution for 2 hours on ice. After two washing steps 
with 1 ml FACS-buffer, cells were stained with 200 µl of a 1:400 dilution of secondary 
antibody in FACS-buffer for 1 hour on ice. To avoid cell clumping and a concentration 
gradient of antibody in solution, cell suspension was regularly shaken during 
incubation. After a further washing step, stained cells were subjected to FACS 
analysis. Used primary and secondary antibodies are listed in Table 3.  
 
 
 
Table 3 Antibodies used for in vitro control of new generated cell lines. 
 
2.8.3 FACS analysis 
FACS analysis was performed using a CYAN LX High Performance Flow Cytometer 
(DakoCytomation, Copenhagen, Denmark). After sample preparation, stained cells 
were filtered to dissolve aggregates and 1 µl of 4',6-diamidino-2-phenylindole (DAPI) 
solution (1 mg/ml) was added. The measurement was performed using appropriate 
filter sets and excitation wavelength. Cell debris and doublets were excluded by 
appropriate gates, using forward versus sideward scatter, respectively sideward 
scatter versus pulse width scatter. At least 10,000 to 50,000 gated cells were 
measured.  
 
2.9 Agarose overlay method 
Cells were seeded in 6-well plates 24 hours before addition of the agarose overlay. 
Culture medium was removed and replaced with 1 ml medium containing 0.6% (w/v) 
agarose (Invitrogen, Carlsbad, USA). The agarose-containing medium was obtained 
by stepwise dilution of complete medium with melted agarose (5% agarose in 
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medium without supplementations, w/v). Before applying the agarose-containing 
medium to the seeded cells, the medium was allowed to cool to 37° C. After 
solidification, 2 ml of complete culture medium without agarose was added to the 
cells. 
 
2.10 Spheroid growth in agarose gel 
To avoid cell growth in a two dimensional way, cells were seeded into an agarose 
gel. Therefore, cells were harvested as soon as reaching approx. 70% confluency. 
The gel was prepared by mixing low melting agarose from Cambrex BioScience 
(Rockland, USA) with medium in a percentage of 10% (w/v). After autoclaving, the 
gel was diluted with medium to 1.2%. Afterwards gel and single cell suspension were 
mixed and 5,000 cells in 1 ml of 0.6% gel were seeded in a 24 well plate (TPP, 
Trasadingen, Switzerland). Grown spheroids were counted after 42 days. Pictures 
were taken with an Infinity 2 camera and Infinity capture software (both: Lumenera 
corporation, Ottawa, Canada). 
 
2.11 In vitro matrigel angiogenesis assay 
Matrigel was purchased from BD (Franklin Lakes, USA). The coating procedure was 
done as described in the BD guidelines for thin gel layers. Matrigel was thawed over 
night at 4 °C. After short homogenization of the gel by pipetting with cooled tips, 10 µl 
of matrigel were added to each well of a µ-slide angiogenesis uncoated chamber 
(ibidi, München, Germany). The slide was incubated for 30 minutes at 37 °C and 
afterwards cells were seeded on the gel layer in an amount of 50,000 cells in 50 µl of 
cell culture medium per well. Cells were grown at 37 °C in 5% CO2 in a humidified 
atmosphere and observed with an axiovert 200 microscope (Zeiss, Jena, Germany). 
Pictures were taken after 24 hours with an Infinity 2 camera and Infinity capture 
software (both: Lumenera corporation, Ottawa, Canada). Image analysis was 
performed with the analysis software from S.Core (Hoehenkirchen, Germany).  
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2.12 qRT-PCR 
Marker gene analysis was done by quantitative polymerase chain reaction. 
Therefore, pairs of primer were designed with the universal probe library of Roche 
and purchased from Metabion (Martinsried, Germany). All pairs of primer, which were 
used for qRT-PCR, are listed in Table 4. Total RNA of in vivo and in vitro samples 
were purified by using two different methods. For the in vitro angiogenesis assay 
samples, 106 cells were seeded on a thin layer of matrigel (BD, Franklin Lakes, USA) 
in a six well plate. Total RNA of cells from one well was purified by phenol-chloroform 
extraction using peqGOLD TriFast kit (Peqlab, Erlangen, Germany). Preparation of 
in vivo RNA-Samples was done with a NucleoSpin RNA II kit (Macherey-Nagel, 
Düren, Germany) using 30 mg of tumor tissue. 5 µg of purified RNA were applied for 
cDNA production. For each qRT-PCR 25 ng cDNA were used for amplification and all 
samples were measured in duplicates. After an activation cycle with 90 °C for 
10 minutes, 45 cycles were performed with a 10 seconds denaturation step at 95 °C, 
30 seconds of annealing at 60 °C and polymerase extension for 1 second at 72 °C. 
The PCR runs were performed with Light Cycler 480 (Roche, Mannheim, Germany). 
For detection, the corresponding probe out of the universal probe library (Roche, 
Mannheim, Germany) was applied. Fold changes were calculated with the ΔΔCt- 
method. As glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta-
actin (Act-B) showed stable unregulated expression status over all tested tumor 
samples in initial experiments, GAPDH was used as reference gene for 
measurements of Oct-4, Thy-1, and aldehyd-dehydrogenase (ALDH-1) and Act-B for 
measurements of HES-1, Notch-3, Notch-1, Nanog, Sox-2, platelet endothelial cell 
adhesion molecule (PECAM-1/CD31), and Intercellular adhesion molecule 2 (ICAM-
2). The ready to use Universal Probe Library (UPL) reference gene assays for 
GAPDH and ACT-B (Roche Diagnostics, Mannheim, Germany) were applied. 
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Table 4 Pairs of primer used for qRT-PCR 
 
2.13 In vitro CPA sensitivity 
In vitro sensitivity was assayed by measuring the DNA content of a cell population 
composed of 25% of CPA activating X39 cells mixed with either HUH-wt, or HUH-
REISO cells, followed by CPA treatment. Generation of cytochrome P450, family 2, 
subfamily b, polypeptide 1 (CYP2B1) transgene expressing X39 cells is described 
previously [38]. In total, 1,500 cells per well were plated in 48-well plates. Twenty-four 
hours after seeding, the culture medium was removed and replaced by either 200 µl 
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of fresh medium or by fresh cell culture medium containing CPA at the indicated 
concentrations. Treated cells and controls were incubated for 5 days in a humidified 
atmosphere containing 5% CO2 at 37 °C. DNA contents were assayed after Hoechst 
33258 incorporation, as previously described [38]. Briefly, cells were lysed with 
Millipore water followed by a freeze–thaw cycle. Cell lysis buffer (1 mM Tris-EDTA, 
pH 7.4, 200 mM NaCl) containing 0.2 ng/ml Hoechst 33258 was applied to each well, 
followed by another freeze–thaw cycle. The DNA content was measured by 
quantifying fluorescence with a plate reader (Tecan, Grödig, Austria) equipped with 
filters for excitation at 360 nm and emission at 465 nm. Relative DNA content was 
calculated using the ratio of DNA content treated /DNA content untreated cell culture.  
 
2.14 Statistical analysis 
U-Test (Mann-Whitney) analysis was performed with WinStat for Exel to proof 
statistical significance in all cases. * stands for p≤0.05, ** for p≤0.01 
 
2.15 Chemicals and reagents 
Chemicals   Supplier 
 
Agarose   Invitrogen (Carlsbad, USA) 
Cyclophosphamide  Sigma (Taufkirchen, Germany) 
DAPI     Sigma Aldrich (Germany)  
DMEM   Invitrogen GmbH(Karlsruhe, Germany)  
EDTA Solution  Invitrogen GmbH (Karlsruhe, Germany) 
Eosin    Sigma (St. Louis, USA) 
Fetal Bovine Serum  Invitrogen GmbH (Karlsruhe, Germany) 
Ham’s F12    Biochrom (Berlin, Germany) 
Haematoxilin   Sigma (St. Louis, USA)  
Hoechst 33258   Sigma Aldrich (Germany) 
Low Melting Agarose Cambrex BioScience (Rockland, USA) 
Matrigel   BD (Franklin Lakes, USA) 
NucleoSpin RNA II Kit  Macherey-Nagel (Düren, Germany) 
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Paraformaldehyde   Sigma Aldrich (Germany) 
Penicillin/Streptomycin Biochrom (Berlin, Germany) 
PeqGOLD TriFast Kit Peqlab (Erlangen, Germany) 
Tissue Freezing Medium  Jung (Nussloch, Germany) 
Tris base    SIGMA-Aldrich (Steinheim, Germany)  
Trypsin   Invitrogen GmbH (Karlsruhe, Germany) 
 
 
. 
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3 RESULTS 
3.1 HUH7 tumors under metronomic CPA therapy in vivo 
Male and female SCID mice bearing subcutaneously implanted human HUH7 tumors 
were treated with metronomically scheduled CPA (75 mg/kg every 6 days). CPA 
treatment was started on day 12 after tumor cell implantation, just as tumors reached 
an average volume of 32 mm3. Metronomically scheduled CPA treatment resulted in 
a significant tumor growth delay. The tumor volume of treated mice was constant at 
around 100 mm3 up to day 75 after tumor cell implantation, whereas tumors in the 
control group exhibited a tumor volume doubling time of 2.5 days. Around day 75 
after tumor cell implantation, tumor volume began to increase in the CPA treated 
group, with a tumor doubling time of 3.5 days, despite ongoing treatment (Figure 3). 
Metronomically scheduled CPA therapy was well tolerated, indicated by a constant 
animal body weight up to day 85 after tumor cell implantation. Further CPA treatment 
resulted in significant loss of body weight, observed in all CPA treated animals. 
Treatment was stopped and the mice were sacrificed as soon as the average body 
weight loss reached 20%. At this therapy endpoint, tumors were collected and 
subjected to macroscopical and histological analyses. Furthermore, tumor cells were 
extracted from viable tumor tissue for characterization and cell culture experiments. 
To establish appropriate control cells (HUH-PAS), HUH7 were grown in male and 
female SCID mice, without exposure to therapy. As soon as tumors reached about 
300 to 400 mm3, viable cells were extracted from the tumor tissue [37]. 
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Figure 3: First implantation study. Subcutaneous human HUH-7 tumors were established 
in SCID mice by injection of 5×106 HUH-7 cells into the flanks of animals. CPA treatment was 
started on day 12 after tumor implantation with 75 mg/kg CPA every sixth days. 
Metronomically scheduled CPA treatment resulted in significant tumor growth delay. Tumor 
volume of treated mice was constant up to day 75 after tumor cell implantation, whereas 
tumors in the control group exhibited a tumor volume doubling time of 2.5 days. Around day 
75 after tumor cell implantation, tumor volume began to increase in the CPA treated group 
despite ongoing treatment with a tumor doubling time of 3.5 days. Experiments performed by 
Michael Günther, PhD thesis LMU 2007 
 
3.2 In vitro control of new generated cell lines 
Reisolated cells (HUH-REISO and HUH-PAS) were analyzed for their human origin 
in vitro to exclude contamination by mouse cells. First, their morphology was checked 
by transmitted light microscopy and compared to the parental HUH-wt. All three cell 
lines grew in isles of small and polygonal cells and hence displayed typical 
morphology for epithelial cells (Figure 4 A-C). No cells with different morphology 
appeared in any cell line. Second, cells were identified by human epidermal growth 
factor-receptor (EGF-receptor) staining for their human origin. The following FACS 
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analysis showed that all cell lines were positive for hEGF-R and had therefore only 
human origin (Figure 4 D-F). 
 
 
 
Figure 4: Microscopic pictures of cell cultures and FACS analysis for human origin of 
all HUH cell lines. HUH-wt (A), HUH-PAS (B) and HUH-REISO (C) showed no differences in 
morphology by transmitted light microscopy. In FACS analysis, cells showed human origin in 
the hEGF-receptor-staining : The whole population of HUH-wt (D), HUH-PAS (E) and HUH-
REISO (F) shifted completely indicated by the red curve in comparison to the correspondent 
control antibody (white curve). 
 
3.3 Influence of CPA therapy on tumor macroscopic 
appearance, tumor histology and functional blood 
flow 
Tumors at the first therapy endpoint were macroscopically assessed. The tumor 
tissue appeared dark and bloody (HUH-REISO) (Figure 5 D), compared to the 
untreated control tumors (HUH-wt) (Figure 5 A). For further characterization and 
evaluation of changes induced by in vivo passaging and CPA treatment, histological 
and immunohistological analyses were performed. Therefore, cryosections were 
stained with hematoxylin/eosin and analyzed by transmitted light microscopy. Tissue 
structure in the original HUH7 xenografts (established from HUH-wt) was compact 
and homogeneous (Figure 5 B). In contrast, resistant tumors (HUH-REISO) exhibited 
an inhomogeneous, sponge-like structure with large cavities within the tumor tissue 
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(Figure 5 E). These cavities were identified as intratumoral pools of blood, due to the 
presence of erythrocytes. To verify this finding, in vivo tumor blood flow was 
visualized by systemically applied Hoechst 33258 dye as a tracer. Several cavities 
within the tumor tissue from resistant HUH-REISO tumors exhibited tracer 
fluorescence, indicating connection with the systemic blood supply (Figure 5 F). For 
comparison, functional blood supply analysis was performed also for the original 
xenografted HUH7 tumors (HUH-wt, Figure 5 C) and re-implanted, treated HUH-PAS 
tumors (Figure 6 A-C). These HUH-PAS control tumors showed a clear diminished 
functional blood flow [37]. 
 
 
 
Figure 5: Macroscopic appearance, tumor histology and functional blood flow. (A-C) 
Untreated parental tumor (HUH-wt) and (D-E) CPA treated in vivo resistant tumor at 
treatment endpoint (HUH-REISO), all collected at day 25 after tumor cell implantation. 
Cryosections (8 µm) were fixed with 4% paraformaldehyde (PFA) and subjected to H/E 
staining: (B) shows untreated parental tumor (HUH-wt) and (E) in vivo resistant tumor at 
treatment endpoint (HUH-REISO). Functional blood flow was visualized by intravenous 
application of Hoechst 33258 dye (blue): (C) displays untreated parental tumor (HUH-wt) and 
(F) in vivo resistant tumor at treatment endpoint (HUH-REISO). Experiments performed by 
Michael Günther, PhD thesis LMU 2007 
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Figure 6: Hoechst-blood-flow comparison of HUH-REISO versus HUH-PAS after 
therapy. Intratumoral functional blood flow was visualized by intravenous application of 
Hoechst 33258 dye (blue). Cryosections (5 µm) of HUH-PAS control tumors after 2xCPA 
treatment (A-C) showed a clear diminished functional blood flow in comparison to treated 
HUH-REISO tumors (D-F). To ensure to have tumor material for analysis, the beginning of 
treatment was late for HUH-PAS tumors, when tumors reached an average volume of 
254 mm3.  
 
3.4 Immunohistochemical analysis of vascular structures 
in xenografts 
Immunohistochemical analysis of the vessel associated markers murine PECAM-
1/CD31 and laminin showed an obvious shift from initial tumor vascularization (HUH-
wt) (Figure 7 A), which is typical for HUH7 xenografts, to tumor tissue with a 
decreased murine vessel density (HUH-REISO) (Figure 7 B) at the therapy endpoint. 
Interestingly, functional blood flow, indicated by Hoechst tracer staining, was not 
closely correlated with immunohistochemically identified vessel structures (Figure 7 
B) [37]. 
Regarding plasticity aspects, tumor tissue was stained for human, besides mouse, 
endothelial specific marker PECAM-1/CD31 (hPECAM-1 and mPECAM-1). Counter 
stain of cell nuclei with DAPI can be seen in Figure 7 C (HUH-wt), Figure 7 G (HUH-
PAS) and Figure 7 K (HUH-REISO). Control stains revealed no hPECAM-1 signal for 
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the parental HUH7 xenografts (Figure 7 E and F), whereas mPECAM-1 (mCD31) 
positive cells showed a large network of vessel (Figure 7 D, highlighted with black 
arrows). Most interestingly, Figure 7 M and merged Figure 7 N showed hPECAM-1 
(hCD31) positive structures (highlighted with white arrows) in re-implanted resistant 
xenografts (HUH-REISO) in close neighborhood to murine vascular structures 
(Figure 7L), indicating HCC plasticity towards the endothelial lineage. Control tumors 
of HUH-PAS, which were treated twice with CPA, showed rare positive signals for 
mPECAM-1 (Figure 7 H) and no positive signal for hPECAM-1 (Figure 7 I). Those 
HUH-PAS tumors had to be treated late, when they had reached an average volume 
of 254 mm³. At an earlier starting point of therapy of these chemoresponsive cells 
there would not be enough tumor material left for reliable analysis (Figure 9).  
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Figure 7: Immunohistochemical analysis for vascular markers in HUH-7 tumors. 
Cryosections (5 µm) of untreated control tumors (HUH-wt) (A) and CPA treated, 
chemoresistant tumors HUH-REISO (B) were fixed with 4% PFA and stained with antibodies 
for murine CD31/PECAM-1 (green) and laminin (yellow). Significant changes in the 
arrangement of laminin and CD31/PECAM-1 positive endothelial cells were detected in CPA 
treated tumors versus control tumors. Functional blood flow was visualized by intravenous 
application of Hoechst 33258 dye (blue). Experiments performed by Michael Günther, PhD 
thesis LMU 2007 (A+B) 
Additional immunohistochemically stained cryosections of untreated HUH-wt (C-F) tumors, 
and HUH-PAS (G-J) or HUH-REISO (K-N) tumors after two times CPA treatment are shown. 
Staining for murine CD31/PECAM-1 (D/H/L, green, highlighted with black arrows) and human 
CD31/PECAM-1 (E/I/M, magenta, highlighted with white arrows) and cell nuclei were 
counterstained with DAPI (C/G/K). Additional to signals from murine CD31/PECAM-1, 
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significant human CD31/PECAM-1 expression was detected in (K-N, HUH-REISO) 
chemoresistant CPA treated tumors, whereas human CD31/PECAM-1 expression was not 
detected in (C-F, HUH-wt and G-J, HUH-PAS) control tumors. 
 
3.5 No evidence of acquired resistance in vitro 
Original HUH7 cells (HUH-wt) and HUH-REISO tumor cells were treated in an in vitro 
co-culture model together with X39 cells, expressing the CYP450 transgene to 
convert CPA in situ into activated CPA [38]. As shown in Figure 8, the in vivo 
resistant HUH-REISO as well as the HUH-wt cells showed CPA concentration-
dependent decrease in cell proliferation, indicating no manifestation of resistance in 
the in vitro setting. Interestingly, the in vivo resistant HUH-REISO displayed an 
insignificantly higher chemosensitivity [37].  
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Figure 8: Sensitivity of parental HUH-wt and isolated HUH-REISO cells towards in situ 
activated CPA. Parental and isolated cells were treated with different concentrations of CPA 
for 3 days together with CPA activating cells X39. Proliferation was determined by measuring 
total DNA content per well. Control experiments were performed in the absence of CPA. 
Mean values ± SD of four measurements are shown. No significant differences were 
observed, nevertheless HUH-REISO cells showed higher sensitivity. Experiments performed 
by Michael Günther, PhD thesis LMU 2007 
 
3.6 Resistance of re-implanted tumors towards 
metronomic CPA therapy in vivo 
Re-isolated HUH-REISO tumor cells and re-isolated in vivo passaged (HUH-PAS) 
cells were implanted in the flank of SCID mice. On day 10 after tumor cell 
implantation, just as average tumor volume reached 14 mm3, mice were subjected to 
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CPA treatment (75 mg/kg, every 6 days). Tumor volume and body weight were 
measured regularly during the treatment. No growth retardation effect was detectable 
for xenografts established from HUH-REISO cells, in contrast to blocked growth of 
xenografts established from in vivo passaged cells (HUH-PAS) (Figure 9). Resistant 
xenografts exhibited an average tumor volume doubling time of approximately 
4.5 days. Metronomically scheduled CPA was again well tolerated, indicated by no 
significant loss in body weight. 
 
 
 
Figure 9: Re-implantation study. Cells isolated from resistant CPA treated tumors (HUH-
REISO) were cultured in vitro and, after several passages, re-implanted in SCID mice (n=6) 
again, with CPA therapy (75 mg/kg every sixth days) starting at day 10 after cell implantation. 
A cell line established from in vivo passaged tumor cells (HUH-PAS) served as control. 
Tumors derived from HUH-REISO cells revealed a tumor volume doubling time (under 
therapy) of 4.5 days, whereas tumor growth in the control group was not evident within the 
observed time. 
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3.7 Regulation of ALDH-1 expression in response to CPA 
therapy in vivo 
As homo sapiens aldehyde dehydrogenase 1 family member A1 (ALDH-1) is a 
known detoxification enzyme and inactivates CPA intermediates, expression levels 
were measured in HUH-REISO and in HUH-PAS during therapy. In absence of CPA 
pressure, only insignificant differences in expression levels were detectable in HUH-
PAS and in HUH-REISO tumors (Figure 10). However, during therapy, expression 
levels of ALDH-1 increased in both xenograft types significantly after two treatments. 
In resistant tumors, ALDH-1 expression levels increased 2.5-fold after six treatments. 
With a p-value of 0.35, the ALDH-1 mRNA levels were not statistically different 
between HUH-PAS and HUH-REISO after the 2nd treatment (2xCPA). 
 
 
 
Figure 10: Aldehyde dehydrogenase I (ALDH-1) expression levels. Influence of CPA 
treatment on expression levels of ALDH-1 was determined in tumor tissue by qRT-PCR 
analysis after two treatments (HUH-PAS and HUH-REISO) and additional four treatments in 
the case of HUH-REISO (n=5). CPA therapy induced ALDH-1 expression in HUH-PAS 
(p=0.009) and in HUH-REISO (p=0.01) xenografts significantly. However, the ALDH-1 level 
was similar for passaged (HUH-PAS) and resistant (HUH-REISO) xenografts, independent of 
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therapy. Statistic evaluation was performed using the Wilcoxon-Mann-Whitney test. P< 0.05 
was considered as significant and indicated by *, p< 0.01 was indicated by **. 
 
3.8 Expression profiles of Thy-1, Oct-4, Sox-2 and Nanog 
in vivo 
For characterization of stemness as a possible cause of tumor cell plasticity, the well 
established stemness markers Thy-1, Oct-4, Sox-2 and Nanog were analyzed, after 
total RNA extraction from tumor tissue. Expression analysis of untreated mice 
revealed that expression levels of Thy-1 (Figure 11 A), Oct-4 (Figure 11 B) and 
Nanog (Figure 11 D) were significantly increased in resistant tumors. In contrast to 
tumors, which were grown from HUH-PAS cells, Sox-2 (Figure 11 C) was not 
significantly increased in resistant tumors. In untreated resistant tumors, Thy-1 
expression levels were about 100-fold (p=0.014) higher, Oct-4 expression levels 
were about 14-fold increased (p=0.027), Sox-2 expression levels were 5-fold 
(p=0.086) upregulated and expression levels for Nanog were detected to be 
increased about 7-fold (p=0.05), in comparison to tumors established from passaged 
tumor cells (Figure 11 A-D). Notably, early after initiation of CPA treatment (two times 
CPA therapy) expression levels of Thy-1, Oct4, Sox2 and Nanog were found to be 
transiently decreased to low expression levels, indicating transient reduction of 
stemness. Moreover, after long term treatment (6 times of CPA therapy), expression 
levels of all four pluripotency markers rose in the resistant tumors (HUH-REISO) 
again. 
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Figure 11: Expression of the plasticity markers Thy-1, Oct-4, Sox-2 and Nanog in 
tumor tissue  
Influence of CPA treatment on expression levels of (A)Thy-1, (B) Oct-4, (C) Sox-2 and (D) 
Nanog was determined in tumor tissue by qRT-PCR analysis without (CPA-) and in tumor 
tissue after two (2xCPA+; HUH-PAS, HUH-REISO) and six (6xCPA+; HUH-REISO) CPA 
treatments (n=5 for each column). CPA-sensitive HUH-PAS tumors would not survive a 
6xCPA- long-term treatment in sufficient extent required for analysis. Statistic evaluation was 
performed using the Wilcoxon-Mann-Whitney test. P< 0.05 was considered as significant and 
indicated by *. 
 
3.9 Expression profiles of Notch-1, Notch-3 and HES-1 
Passaged (HUH-PAS) and resistant (HUH-REISO) tumor bearing mice were treated 
by metronomic CPA therapy. Interestingly, Notch-1 expression (Figure 12 A) was 
conversely regulated in comparison to Thy-1, Oct-4, Sox-2 and Nanog. Significant 
increase of Notch-1 (about 3-fold) expression was detected only in in vivo passaged 
tumors (p=0.028) after two times of CPA treatment. Regulation of Notch-1 in already 
resistant tumors was not observable. Even after six chemotherapy treatment cycles, 
Notch-1 expression levels stayed constant. However, expression of HES-1, a target 
gene of the Notch pathway, was upregulated after two CPA-treatments in passaged 
and in resistant tumors. In HUH-PAS tumors, levels of HES-1 were 2.3 fold higher 
(p=0.0090), in HUH-REISO tumors 2.4 fold higher (p=0.0143) (Figure 12 B), if 
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compared with the corresponding non-treated counterparts. After six treatments, 
HES-1 expression levels sank to the levels of untreated tumors. HES-1 expression 
levels were about 2-fold higher in in vivo passaged tumors, compared to in vivo 
resistant tumors, independent of the treatment. Congruent to Notch-1 regulation, 
significant increase of Notch-3 expression levels (about 3.7 fold) were detected in 
in vivo passaged tumors (p=0.0247) after two times of CPA treatment (Figure 12 C). 
In resistant tumors an increased level about 2-fold (p=0.0446), which appeared after 
two treatments, disappeared after further four treatments.  
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Figure 12 Expression of Notch-1, Notch-3 and its downstream target HES-1 in tumor 
tissue 
Influence of CPA treatment on expression levels of Notch-3, Notch-1 and its downstream 
target HES-1 were determined in tumor tissue by qRT-PCR analysis before and after two 
CPA-treatments (HUH-PAS and HUH-REISO) and further four treatments in the case of 
HUH-REISO (n=5). (A) In contrast to significant induction of Notch-1 expression by two CPA 
therapies in passaged tumors (HUH-PAS), Notch-1 expression levels in chemoresistant 
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tumors (HUH-REISO) remained not significantly altered even after four further CPA-
treatments. Initial expression levels of Notch-1 were not significantly different.  
(B) HES-1 expression levels were detected to be significantly induced after two treatments 
for passaged (HUH-PAS) and chemoresistant tumors (HUH-REISO). Initial expression levels 
and expression levels after two CPA-treatments remained significantly low compared to 
tumors grown from in vivo passaged cells (HUH-PAS). After four further treatments, 
expression levels again reached initial HES-1 expression in chemoresistant tumors (HUH-
REISO). 
(C) Notch-3 showed in both groups HUH-PAS (p=0.0247) and HUH-REISO (p=0.0446) 
significantly upregulated levels after two times of CPA therapy. After additional four CPA 
treatments, level of Notch-3 in HUH-REISO dropped back on base levels.  
 
3.10 Anchorage independent growth of HUH-wt, HUH-
PAS and HUH-REISO spheroids 
For characterization of cell dependency on essential matrix signaling, the capacity for 
anchorage-independent growth was tested by their ability to form colonies in soft 
agar. Multicellular spheroids were counted 42 days after embedding the single cell 
suspension (5,000 cells/well) in solid medium (Figure 13). The lowest spheroid 
forming capacity was detected for the HUH-wt, which developed only 9 spheroids out 
of 5,000 seeded cells. Interestingly, cells from HUH-PAS exhibited a 15-fold 
increased capacity (140 spheroids / 5,000 seeded cells) for anchorage-independent 
growth, in comparison to the original cell line. Spheroid forming capacity of HUH-
REISO cells, building around 104 spheroids / 5,000 seeded cells, was 11-fold 
increased compared to HUH-wt but lower compared to HUH-PAS. No significant 
differences spheroid forming capacity was observed between resistant and non-
resistant tumor cells, as only HUH-wt built far less spheroids than the other two cell 
lines.  
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Figure 13 Anchorage independent growth. Spheroid forming capacity was determined by 
counting multicellular spheroids under the microscope (horizontal bar: median), resulting in 
low spheroid forming capacity (<20 spheroids/well) for parental HUH-7 cells (HUH-wt) and 
significantly increased forming potential in cells, which were derived from xenografts (HUH-
PAS and HUH-REISO). 
 
Nevertheless, the spheroids differed in their appearance. The parental HUH-wt cells 
(Figure 14 A) and in vivo passaged cells (Figure 14 B) built up very compact and 
homogeneous spheroids. In contrast, spheroids from the resistant tumor cells (Figure 
14 C) were characterized by cavities within the spheroids. These findings could be 
consolidated by HE staining of 10 µm cryosections of spheroids. HUH-wt spheroids 
(Figure 14 D) and HUH-PAS spheroids (Figure 14 E) showed uniform and continuous 
tissue without cavities, whereas HUH-REISO spheroids (Figure 14 F) presented a 
sponge-like structure inside the spheroids.  
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Figure 14: Anchorage independent growth. Multicellular spheroids grew from a single cell 
suspension of (A) parental HUH-7 cells (HUH-wt), (B) in vivo passaged HUH7 cells (HUH-
PAS) and (C) chemoresistant cells (HUH-REISO) in low melting agarose for 42 days and 
pictures were taken under a phase contrast microscope. Spheroid tissue organization was 
detected by H/E staining of cryoslides. You can see in (D) parental HUH-7 cells (HUH-wt), in 
(E) in vivo passaged HUH7 cells (HUH-PAS) and in (F) chemoresistant cells (HUH-REISO). 
 
3.11 Endothelial trans-differentiation in vitro 
To evaluate the potential of tumor cells to transdifferentiate into an endothelial 
phenotype, a tube formation assay (Figure 15) was performed. At first, HUH-wt, 
HUH-PAS, and HUH-REISO cells were pre-cultured under conventional conditions 
(Figure 15 A-C) or under a thin layer of solid medium (“agarose overlay”, Figure 15 
D-F) for six weeks. In this diffusion controlled environment [38], supply with nutrients 
and oxygen and moreover, dilution of autocrine and paracrine factors is limited, 
compared to conventional cell culture systems. After the pre-culture, the six different 
cell culture groups were subjected to a conventional matrigel assay (Figure 15 A-F). 
Only HUH-REISO cells, pre-cultured by agarose overlay, showed enough plasticity to 
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form endothelial like tubes within 4 hours (data not shown). After 24 h, the network 
was fully trained in this group (Figure 15 F), whereas HUH-wt (Figure 15 D) and 
HUH-PAS (Figure 15 E) cells showed no striking tube formation. Moreover, tube 
formation was not detectable in all three tumor cell groups pre-cultured under 
conventional conditions (Figure 15 A-C).  
 
 
 
Figure 15 Tube formation assay. Tumor cells were seeded on matrigel after conventional 
cell culture (21% Oxygen / 37 °C) or after a 42 days culture in a diffusion limited environment 
with reduced oxygen and nutrient supply. Pictures were taken 24 hours after plating. (A) 
Parental HUH7 (HUH-wt), (B) in vivo passaged (HUH-PAS) and (C) chemoresistant (HUH-
REISO) cells derived from conventional cell culture did not show tube formation, whereas in 
the case of cells, derived from the diffusion limited environment, the (F) chemoresistant 
tumor cells (HUH-REISO) showed significant tube formation potential in the matrigel assay, 
in comparison to (D) HUH-wt and (E) HUH-PAS (n=5). 
 
Quantification of tube formation in matrigel was performed via software based 
analysis (Figure 16 A-J). Comparison of HUH-wt, HUH-PAS, and HUH-REISO (all 
pre-cultured by agarose overlay) revealed a far higher number of branching points 
(Figure 16 G) and tubes (Figure 16 H), a very extended length of skeleton (Figure 16 
I), and a decreased amount of confluent areas without tube formation (Figure 16 J) 
for HUH-REISO cells. 
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Figure 16 Software based analysis of matrigel assay. The software based analysis 
system projected a mask on pictures from transmitted light microscopy of matrigel assay 
(same pictures as described in Fig. 9D, E and F). In white are confluent areas, in blue are 
nodular structures coloured and built counted tubes with orange and red coloured areas. The 
tube skeleton is indicated in the thin white lines and their crossing points are defined as 
branching points. As HUH-wt (A) and HUH-PAS (B) revealed no tube formation, the 
projected mask is hardly coloured (D and E). HUH-REISO (C) showed low amount of 
confluent white area and accordingly contained all other aspects of functional tube formation 
(F). Software based analysis of pictures revealed a significantly increased (G) number of 
branching points, (H) overall number of tubes and (I) total length skeleton in chemoresistant 
cells (HUH-REISO) in comparison to both control cell lines (HUH-wt and HUH-PAS). 
Consequently, (J) the total confluent area was significantly decreased for HUH-REISO (n=3). 
 
Furthermore, expression levels of endothelial markers (CD31/PECAM-1, ICAM-2, 
VEGFR2, VE-cadherin and vWF) of agarose overlay HUH-REISO cells, showing 
positive tube formation, were compared to the corresponding standard culture HUH-
REISO (Figure 17 A and B). Expression levels were determined after the matrigel 
assay. In agarose overlay HUH-REISO cells, ICAM-2 (p=0.009) (Figure 17 A), as 
well as CD31/PECAM-1 (p=0.028) (Figure 17 B) were significantly upregulated. 
Expression of the other endothelial markers was not detectable in HUH-REISO under 
any culture condition. 
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Figure 17 Expression of endothelial markers after hypoxic conditions. A qRT-PCR 
analysis, performed after the tube formation assay on the endothelial markers (A) ICAM-2 
and (B) PECAM-1/CD31, revealed significantly increased expression levels for cells derived 
from the diffusion limited environment culture compared to conventional cultured cells, which 
did not show tube forming potential (n=6).  
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4 DISCUSSION 
4.1 The HCC xenograft mouse model 
In the present thesis, acquired in vivo chemoresistance against metronomic 
cyclophosphamide (CPA) treatment was studied in a human hepatocellular 
carcinoma HUH7 xenograft mouse model. During treatment, a two phase 
development of tumor progression was observable: In the beginning of treatment 
(response phase), tumor progression was significantly decreased, indicated by 
constant tumor volume for about 75 days. In the following second phase (escape 
phase), tumor volume increased with a tumor volume doubling time of 3.5 days 
despite ongoing therapeutic intervention (Figure 3).  
Viable tumor cells were extracted from such resistant tumors (HUH-REISO), whereas 
control cells (HUH-PAS) were obtained from in vivo passaging HUH7 tumor cells 
without CPA treatment. Subsequently, HUH-PAS and HUH-REISO were 
characterized and identified in terms of cell morphology and representative human 
epidermal growth factor (EGF receptor) expression for their human origin (Figure 4). 
 
4.2 No resistance in vitro, no well-known mechanism 
Interestingly, in vivo chemoresistant HUH-REISO did not manifest their drug resistant 
phenotype in a two-dimensional monolayer culture in presence of in situ activated 
CPA (Figure 8). However, mechanisms like upregulated detoxicating enzymes, efflux 
pumps, increased DNA repairing, and deficient apoptosis are not limited to the  
in vivo situation and should be also evident in vitro. In addition, significant changes in 
macroscopic appearance and tumor tissue organization of chemoresistant tumors 
indicate resistance mechanisms, which were only executed in the in vivo situation.  
 
4.3 Manifested chemoresistance directly after re-
implantation 
An endogenous imprinted component for in vivo chemoresistance was obvious, as 
the chemoresistant phenotype of isolated tumor cells was immediately manifested 
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again after re-implantation and reapplied chemotherapy. Differences in experimental 
setup were avoided by a setting where every mouse bore two tumors. In vivo 
passaged only HUH-PAS were implanted into the left flank and chemoresistant HUH- 
REISO into the right flank. In the re-implantation experiment, chemoresistance was 
manifested in HUH-REISO lacking the response phase against administered CPA. In 
contrast, HUH-PAS, which had only been adjusted to the in vivo environment but not 
to the CPA treatment, remained sensitive (Figure 9) in a response phase. This 
special experimental setup also proved sufficient activation of CPA, as HUH-PAS 
were sensitive against therapy. 
 
4.4 Detoxification of CPA by ALDH-1 
The qRT-PCR assay on in vivo samples revealed no significant difference in basal 
expression of the detoxification enzyme ALDH-1 (Figure 10), which converts 
aldophosphamide into carboxyphosphamide. ALDH-1 expression was detected to be 
significant upregulated in vivo during therapeutic pressure. However, the extent of 
upregulation was not significantly different in chemosensitive and chemoresistant 
tumors. The detected chemosensitivity of HUH-PAS exclude resistance by unspecific 
selection processes in vivo, which might change cellular properties independently of 
therapeutic pressure [39, 40].  
 
4.5 Blood-flow and supplementation in tumors 
As metronomic CPA treatment is known to suppress tumor angiogenesis [25], 
functional blood flow analysis was performed, revealing blood flow in a part of the 
newly formed cavities of chemoresistant tumors (Figure 5 F). In contrast to untreated 
animals, blood flow was not obligatory co-localized with immunohistochemical 
detected laminin and mouse PECAM-1/CD31 signal (Figure 7 B). Further analysis on 
human vessel markers revealed the presence of cells expressing human PECAM-
1/CD31 (Figure 7 M/N) within the tumor, indicating plasticity of the tumor cells and 
initiation of differentiation towards the endothelial lineage. This differentiation was 
observed only in HUH-REISO. In HUH-PAS the CPA therapy led to a deletion of 
murine vessels (Figure 7 H), while the capacity of building new human vessels was 
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not observed. As HUH-REISO showed no diminished blood-flow (Figure 6) and also 
a supplementation of destroyed murine vessels by human endothelial cells, 
resistance is partly caused by a better blood-supplementation due to the higher 
plasticity of HUH-REISO. Better blood-supplementation leading to higher drug 
delivery into the tumor presumably requires also other detoxification mechanisms for 
the resistance. The higher levels of ALDH-1 in HUH-REISO (6xCPA,Figure 10) are 
consistent with this hypothesis. Therefore, further changes in the microenvironment 
and proteome of the resistant tumor cells remain to be examined in future work.  
 
4.6 Anchorage independent growth and spheroid 
morphology 
Plasticity becomes often apparent in combination with the capacity of self-renewal 
and potential of anchorage independent growth, frequently assessed in spheroid 
building capacity assays [41, 42]. In such an assay, no significant differences 
between resistant and non-resistant tumor cells could be observed (Figure 13). 
However, this fact is not surprisingly at all as there is only rare human tissue as 
renewable and regenerative as the liver tissue. Consequently, all cell lines of our liver 
cancer showed a good potential of anchorage independent growth, especially in the 
selected cells of in vivo pressure. Nevertheless, a big difference was observable 
between the different cell lines looking into the inner area of the spheroids. In 
contrast to spheroids derived from HUH-wt (Figure 14 A/D) or from in vivo passaged 
HUH-PAS cells (Figure 14 B/E), spheroids formed by HUH-REISO cells revealed the 
formation of cavities and tubular structures (Figure 14 C/F). This indicated cellular 
changes, which differed from the environmental conditioning of in vivo passaging. 
The consequent sponge-like growth (both in spheroids and in tumors) might also 
ensure an easier supplementation of HUH-REISO tissue with nutrients and oxygen 
than in compact HUH-PAS and HUH-wt tissue. Thus, for experiments HUH-PAS cells 
were used as an adequate control, to characterize development of chemoresistance 
in vivo.  
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4.7 Stemness and plasticity makers by qRT-PCR 
Taking the detected plasticity into account, HUH-PAS and HUH-REISO in vivo 
tumors were analyzed for expression profiles of markers, which are highly expressed 
in embryonic cells and described in recent papers about tumor initiating cells [43-45].  
Expression of Oct-4 plays a crucial role in maintaining pluripotency in stem cells [43]. 
Additionally, Sox-2 and Nanog expression contribute to plasticity, self-renewal and 
stemness [44]. Especially, in the context of HCC tumor stem cell research, Thy-1 
expression is discussed as one crucial regulator of stemness and its upregulation is 
described in the context of chemoresistance [45]. In the absence of chemotherapy 
in vivo (-CPA, Figure 11 A-D), qRT-PCR revealed significantly increased expression 
levels of Thy-1, Oct-4, Sox-2 and Nanog in the re-implanted chemoresistant HUH-
REISO tumors compared with the in vivo passaged HUH-PAS control tumors. This 
indicates an inherent difference of the chemosensitive HUH-PAS and chemoresistent 
HUH-REISO tumors, with an enrichment of tumor cells with a reprogrammed, 
embryonic-like status for HUH-REISO. To monitor the response of HUH-REISO 
tumors towards CPA treatment with time, qRT-PCR analyses were performed also 
after 2x CPA and 6x CPA treatment. HUH-PAS tumors were analyzed in parallel, but 
after 2 treatments only. The late time point (6x CPA) was not evaluated due to the 
lack of tumor outgrowth on the one hand, or upon outgrowth conversion into a 
REISO-type resistant tumor on the other hand. At the earlier (2xCPA) time point, 
resistance was not yet established for HUH-PAS (day 14, no tumor outgrowth,Figure 
9). In vivo passaging alone generated only few cells with pluripotent capacities (HUH-
PAS, CPA-), but these cells differentiated very fast or got lost under therapeutic 
pressure (HUH-PAS, 2xCPA). In contrast, HUH-REISO generate tumor tissue 
containing a pluripotent sub-population (Figure 11, -CPA). Upon CPA treatment, 
HUH-REISO tumors continue to grow, but partly lost their pluripotent stem cell 
population during the acute response to the first two treatments (Figure 11, HUH-
REISO, 2xCPA), presumably by differentiation. However, chemoresistent tumors 
were able to regenerate the pool of stem cells (Figure 11, HUH-REISO, 6xCPA) and 
reached a “steady-state” with stemness markers again. Based on these stemness 
marker results, recent papers [46-49] and my results regarding Notch-pathways, I 
propose the hypothesis shown in Figure 18.  
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4.8 Notch-1 the important factor in keeping pluripotency 
In line with literature [46], the process of reprogramming was connected to induction 
of Notch-1 expression, as a first response to chemotherapeutic pressure (Figure 12 
A). Induction of Notch-1 leads to the expression of GIMAP5 [46], which is anti-
apoptotic and has potential to improve cell survival. ALDH-1 was simultaneously 
induced (Figure 10) and led to cell survival under therapeutic pressure. Furthermore, 
induction of HES-1, which is a downstream target of Notch-1, was observable (Figure 
12 B). HES-1 belongs to the basic helix loop helix family of transcription factors and 
is described by Kageyama et al. as a crucial factor in many tissues to maintain the 
status of pluripotency [47]. Notch-1 and HES-1 were only upregulated in the 
response phase of therapy, indicating an initial key factor in this process. In the 
escape phase of already chemoresistant tumors, Notch-1 was steadily regulated 
under chemotherapeutic pressure, indicating that Notch-1 was essential for the 
preservation of the reprogrammed status, once Thy-1, Oct-4, Sox-2 and Nanog 
provides pluripotency and self-renewal. 
 
4.9 Notch-3 the important factor in endothelial trans-
differentiation 
Surprisingly, after two treatments with CPA, expression levels of Thy-1, Oct-4, Sox-2 
and Nanog were decreased in HUH-REISO (Figure 11 A-D), indicating a process of 
differentiation, which obviously antagonize further enrichment of this subpopulation at 
this point of treatment. This correlated with the induction of Notch-3 expression. The 
Notch-3 pathway is described as an important signalling pathway in the development 
of vascularization. N. Lawson et al. [48, 49] showed the important role of Notch-3 in 
arterial cell fate during blood vessel development. However, after prolonged CPA 
treatment, expression levels of all pluripotency markers recovered. The initial 
expression profile of Notch-3 and the profile of Thy-1, Oct-4, Sox-2 and Nanog 
pointed to an adaptation process, as a response to acute chemotherapeutic 
pressure.  
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4.10 A pool of pluripotent cells 
Obviously, differentiation was repressed again after adaptation and the balance 
returned to enrichment of pluripotent cells. An important step to the in vivo 
chemoresistance in our model was therefore the development of a pool of cells, 
which reveal increased levels of pluripotency markers and obviously help to 
overcome chemotherapeutic pressure by initiation of differentiation (Figure 18). In 
contrast to chemoresistant tumors, the CPA therapy in chemosensitive tumors led to 
the induction of differentiation processes and cell death, which in the beginning of 
treatment nearly flushed out the whole pool of pluripotent tumor cells. Recovering of 
this pool took long time (growth delay phase Figure 9) and led, beside other 
mechanisms, in the end to resistance (Figure 3). 
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Figure 18 Acquired chemoresistance towards metronomic CPA therapy – a 
hypothetical model of the equilibrium between stem cells and endothelial like cells in 
HUH-REISO. During therapeutic pressure tumor cells acquire stepwise pluripotency. 
Reprogramming is associated with regulations of the Notch-pathway (Notch-1), resulting in 
enrichment of cells with increased expression levels of Thy-1, Oct-4, Sox-2 and Nanog. This 
pool of cells is the basis for increased adaptiveness of the tumor to therapy effects as 
hypoxia. Differentiation to a functional endothelial like phenotype, connected with tissue 
reorganization, counteracts antiangiogenic therapy. Finally, in the chemoresistant tumors 
exists an equilibrium between differentiation and self-renewal. In contrast to chemoresistant 
tumors, induction of Notch-3 expression in chemosensitive tumors leads to the induction of a 
differentiation process, which nearly flushes out the whole pool of pluripotent tumor cells. 
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4.11 Endothelial trans-differentiation triggered by 
oxygen limitation 
This differentiation process, resulting in the reorganization of tumor tissue, helped 
tumors to escape the metronomic treatment. To investigate the trigger, which caused 
differentiation, HUH-wt, HUH-PAS, and HUH-REISO cells, were pre-cultured in an 
in vitro cell culture system, which mimics several features of solid tumors under 
therapeutic pressure. In a following matrigel tube formation assay, usually performed 
for angiogenesis studies [50], HUH-REISO cells showed tube formation capacity 
(Figure 15 F), whereas cells pre-cultured under conventional conditions showed no 
functionality (Figure 15 C). Importantly, HUH-wt and HUH-PAS revealed no tube 
formation potential, independently of pre-culture conditions. Obviously, initiation of 
differentiation only took place in an environment, which was characterized by 
limitation of oxygen supply and simultaneous diffusion limitation of paracrine and 
autocrine factors. In recent studies, the phenomena of tumor cell tube formation on 
matrigel was detected e.g. for glioblastoma, breast cancer [51] and multiple myeloma 
[52]. In several studies, the feature of tube formation was independent from the 
expression of endothelial markers (vascular mimicry) [53]. However, in the case of 
HUH-REISO cells, tube formation was associated with induction of the endothelial 
genes PECAM-1/CD31 and ICAM-2 (Figure 17 A and B). In contrast, other 
endothelial marker genes as vWF, VEGFR2 and VE-cadherin were neither 
expressed, nor regulated. Expression of endothelial genes was published by 
Bussolati et al. and Bruno et al., who detected induction of endothelial marker 
expression, derived from tumor initiating cells (tumor stem cells) by treatment via 
VEGF [54] or after xenografting [55]. Apparently, HUH-REISO cells, or at least a 
subpopulation acquired a reprogrammed status characterized by enormous plasticity. 
This pool of cells reacted on environmental requirements by initiation of differentiation 
in specialized cells to maintain a balanced tumor microenvironment, ensured 
sufficient oxygen and nutrient supply and finally counteracted metronomic therapy. 
It remains to be investigated whether the plasticity as observed with HUH7 is 
especially pronounced with HCC or other tumors. In this regard, recent interesting 
observations from normal liver organogenesis [56]. For long time it had been 
assumed that the endoderm generates the hepatocytes, while the mesoderm 
generates the liver endothelial cells. Now it was discovered that the endodermal cells 
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can generate approximately 15% of the liver endothelial cells, demonstrating a 
special plasticity in endodermal liver progenitor cells.  
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5 CONCLUSION AND OUTLOOK 
In conclusion, studying the escape mechanism towards metronomically applied CPA 
therapy in a HCC xenograft model revealed a multistep process, going beyond 
unspecific enrichment of a certain subpopulation by the in vivo tumor environment. 
First step of this process was the enrichment of detoxicating enzyme ALDH-1 in 
combination with upregulation of the Notch1-pathway and its protective downstream 
effector proteins. As a result, therapy could be overcome by this mechanism. The 
second step was a selection process of pluripotent, stem cell marker expressing cells 
with pluripotent trans-differentiation capacities. Their capacities included that these 
cells have increased endothelial trans-differentiation in vivo and in vitro. Functionality 
of such endothelial-like cells helped resistant tumors to overcome anti-angiogenic 
therapy and was the most important finding of this study. Further examinations, on 
how modification of Notch signalling may impact cell plasticity and differentiation 
remain to be explored in future. Also co-medication studies in vivo with CPA in 
combination with Notch-antibodies or agents which interrupt Notch-pathway could be 
enlightning. Of course, a proteomics approach of the different cell lines would be a 
perfect tool for further examinations. 
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6 SUMMARY 
Chemotherapeutic treatment of hepatocellular carcinoma often leads to 
chemoresistance during therapy or upon relapse of tumors. For the development of 
better treatments, a better understanding of biochemical changes in the resistant 
tumors is needed. Therefore, especially in vivo models are very important tools to 
generate standardized cell-material, which can be examined by high throughput 
techniques. Thus, it should be possible to find new targets for therapy or even for 
diagnostic. This thesis focusses on the characterization of the in vivo chemoresistant 
human hepatocellular carcinoma HUH-REISO established from a metronomically 
cyclophosphamide (CPA) treated HUH7 xenograft mouse model.  
First step of the work was the establishment of the xenograft mouse model. SCID 
mice bearing subcutaneous HUH7 tumors were treated i.p. with 75 mg/kg CPA every 
six days. After 10 weeks of response to the therapy, the tumor growth relapsed and 
tissue grew with very fast doubling time again, despite of ongoing treatment. This 
aggressive manner of growth under therapy could be also observed in a re-
implantation study where the reisolated CPA chemoresistant HUH-REISO tumors 
grew without a lag phase, indicating an endogenous imprinted component. To 
evaluate this, tumors were examined by immunohistochemistry, a functional blood-
flow Hoechst dye assay, and qRT-PCR for ALDH-1, Notch-1, Notch-3, HES-1, Thy-1, 
Oct-4, Sox-2 and Nanog mRNA levels.  
Histochemical analysis of HUH-REISO tumors revealed significant changes in host 
vascularization of tumors and especially in expression of the tumor-derived human 
endothelial marker gene PECAM-1/CD31 in HUH-REISO in comparison to parental 
HUH-7 cells and in vivo passaged HUH-PAS cells (in vivo grown without 
chemotherapeutic CPA pressure). The pronounced network of host murine 
vascularization in parental HUH-7 tumors was completely substituted by a network of 
human and murine vessel-like structures in HUH-REISO tumors under therapy.  
In addition, cell lines of these tumors were analyzed in endothelial trans-
differentiation studies on matrigel. In those studies with limited oxygen and metabolite 
diffusion, followed by a matrigel assay, only the chemoresistant HUH-REISO cells 
exhibited tube formation potential and expression of human endothelial markers 
ICAM-2 and PECAM-1/CD31. Such a trans-differentiation capacity requires a lineage 
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of cells with pluripotent capacities like so called tumor stem cells. Indeed, I could 
show in a comparative study on stemness and plasticity markers that Thy-1, Oct-4, 
Sox-2 and Nanog were upregulated in resistant xenografts. Furthermore, under 
therapeutic pressure by CPA, tumors of HUH-PAS and HUH-REISO displayed 
regulations in Notch-1 and Notch-3 expression, which I could also show by qRT-
PCR. Notch-1 raised in HUH-PAS under therapeutic pressure, meanwhile it was 
conversely regulated in comparison to Thy-1, Oct-4, Sox-2 and Nanog in HUH-
REISO. In both groups Notch-3 was inducible by 2 times CPA treatment and fell back 
on base level after further four therapeutic cycles in HUH-REISO. 
To conclude all these finding: chemoresistance of HUH-REISO was not manifested 
under standard in vitro, but only under in vivo conditions. HUH-REISO cells showed 
increased pluripotent capacities and the ability of trans-differentiation to endothelial 
like cells in vitro and in vivo. These cells expressed typical endothelial surface marker 
and functionality. Although the mechanism behind chemoresistance of HUH-REISO 
and involvement of plasticity remains to be clarified, we hypothesize that the 
observed Notch regulations and upregulation of stemness genes in resistant 
xenografts are involved in the observed cell plasticity. 
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7 APPENDIX 
7.1 Abbreviations 
Act-B   - Beta actin 
ALDH-1  -  Aldehyde dehydrogenase 
cDNA   - copy deoxyribonucleic acid 
CD XY   - Cluster of differentiation protein number xy 
CO2   - Carbon dioxide 
CPA   - Cyclophosphamide 
CYP2B1  - Cytochrome P450, family 2, subfamily B, polypeptide 1 
DAPI   - 4′,6-Diamidin-2-phenylindol  
DMEM  - Dulbecco's modified eagle medium 
EDTA   - Ethylenediamine tetra acetic acid  
EGF   - Epidermal growth factor 
EGF-R  - Epidermal growth factor receptor 
FACS   - Fluorescence-activated cell sorting  
FBS   - Fetal bovine serum  
FGF   - Fibroblast growth factor 
G (needle)  - Gauge 
GAPDH  - Glycerinaldehyde-3-phosphat-Dehydrogenase  
HCC   - Human Hepatocellular Carcinoma 
HES-1  - Hairy and enhancer of split-1  
HE-stain  - Hämatoxylin eosin staining 
HIF-1α  - Hypoxia inducible factor 1 alpha 
HUH-7  - Human Hepatoma cell line 7 
ICAM-2  - Intercellular adhesion molecule 2   
i.p.   - Intraperitoneal application 
i.v.    Intravenous application 
MTD    Maximum tolerated dose 
NaCl   - Sodium chloride 
Oct-4   - Octamer binding transcription factor 4  
p / p-value  - Probability of obtaining a test statistic result 
PBS   - Phosphate buffered saline 
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PCR   - Polymerase chain reaction 
PECAM-1/CD31 - Platelet endothelial cell adhesion molecule  
PFA   - Paraformaldehyde 
PIGF   - Phosphatidylinositol-glycan biosynthesis class F protein  
qRT-PCR  - Quantitative realtime polymerase chain reaction 
RNA   - ribonucleic acid  
SCID   - Severe Combined Immunodeficiency  
SD   - Standard deviation  
Sox-2   - Sex determining region Y-box 2  
Thy-1 / CD90 - Thymocyte differentiation antigen 1  
Tris   - Trometamol 
VE-cadherin  - Vascular endothelial- cadherin 
VEGF   - Vascular endothelial growth factor 
wt   - wild-type 
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7.2 Publication 
Marfels, C., Hoehn, M., Wagner, E., Günther, M. (2013) Characterization of in vivo 
chemoresistant human hepatocellular carcinoma cells with transendothelial 
differentiation capacities. BMC Cancer 13, 176. 
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